Cargando…

Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy

OBJECTIVE: To investigate the efficacy and safety of febuxostat on renal function in CKD stage 3 diabetic nephropathy patients. METHODS: Patients in our hospital with chronic kidney disease (CKD) stage 3 diabetic nephropathy (DN) complicated by high serum uric acid (360 µmol/L) were recruited. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Huang, Yongling, Zhu, Shuying, Zheng, Jiali, Wang, Yanling, Zhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Nefrologia 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860659/ https://www.ncbi.nlm.nih.gov/pubmed/32701116 http://dx.doi.org/10.1590/2175-8239-JBN-2019-0091

Ejemplares similares

Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
por: Zhang, Peiyu, et al.
Publicado: (2022)

Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy
por: He, Li, et al.
Publicado: (2017)

Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021)

Febuxostat Attenuates Renal Damage besides Exerting Hypouricemic Effect in Streptozotocin-Induced Diabetic Rats
por: Ran, Jianmin, et al.
Publicado: (2017)

Urinary peptidome analysis in CKD and IgA nephropathy
por: Li, Zewen, et al.
Publicado: (2023)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy
por: Beddhu, Srinivasan, et al.
Publicado: (2016)

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
por: Zhao, Zhen Xiong, et al.
Publicado: (2022)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice
por: Mizuno, Yu, et al.
Publicado: (2019)

Diabetic Nephropathy and CKD—Analysis of Individual Patient Serum Creatinine Trajectories: A Forgotten Diagnostic Methodology for Diabetic CKD Prognostication and Prediction
por: Onuigbo, Macaulay Amechi Chukwukadibia, et al.
Publicado: (2015)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis
por: Zheng, Yanqun, et al.
Publicado: (2022)

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

Diabetic Nephropathy: A Comparison of the Clinical and Pathological Features between the CKD Risk Classification and the Classification of Diabetic Nephropathy 2014 in Japan
por: Furuichi, Kengo, et al.
Publicado: (2018)

Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation
por: Nanmoku, Koji, et al.
Publicado: (2017)

Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis
por: Lin, Tsu-Chen, et al.
Publicado: (2019)

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
por: Peng, Yueh-Lung, et al.
Publicado: (2020)

A Newly Recognized Endemic Region of CKD of Undetermined Etiology (CKDu) in South India—“Tondaimandalam Nephropathy”
por: Parameswaran, Sreejith, et al.
Publicado: (2020)

Contribution of CKD to mortality in middle-aged and elderly people with diabetes: the China Health and Retirement Longitudinal Study: CKD was a chronic stressor for diabetics
por: Liao, Xihong, et al.
Publicado: (2023)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report
por: Poh, Xue Er, et al.
Publicado: (2017)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease
por: Nata, Naowanit, et al.
Publicado: (2023)

Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells
por: Hao, Jianli, et al.
Publicado: (2021)

Sleep quality, autonomic dysfunction and renal function in diabetic patients with pre-CKD phase
por: Kadoya, Manabu, et al.
Publicado: (2021)

Effectiveness of renal sympathetic denervation in renal function and blood pressure in CKD and non-CKD patients with controlled vs. uncontrolled hypertension
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2016)

POS-465 C1Q NEPHROPATHY CAUSING ADVANCED CKD IN THE COVID 19 ERA : A PATIENT WHO RECOVERED TO BASELINE RENAL FUNCTION POST SARS-COV2 AKI ON CKD
por: BASHIR, N., et al.
Publicado: (2022)

Analysis of the Renal Protection and Antioxidative Stress Effects of Panax notoginseng Saponins in Diabetic Nephropathy Mice
por: Mi, Wei, et al.
Publicado: (2022)

Macrophage phenotype and its relationship with renal function in human diabetic nephropathy
por: Zhang, Xiaoliang, et al.
Publicado: (2019)

Efficacy and safety of febuxostat in elderly female patients
por: Mizuno, Tomohiro, et al.
Publicado: (2014)

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
por: Kraev, Krasimir Iliev, et al.
Publicado: (2023)

Risk factors analysis for hyperuricemic nephropathy among CKD stages 3–4 patients: an epidemiological study of hyperuricemia in CKD stages 3–4 patients in Ningbo, China
por: Wu, Yong-Yao, et al.
Publicado: (2018)

Correction to “Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells”
por: Hao, Jianli, et al.
Publicado: (2022)

CKD of Unknown Origin in Central America: The Case for a Mesoamerican Nephropathy
por: Correa-Rotter, Ricardo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b92ldqj0uunbms12ju36bhtd6t